Use of mHealth interventions in the management of chemotherapy-related adverse drug reactions

BackgroundChemotherapy remains a cornerstone of cancer treatment but carries a substantial burden of adverse drug reactions (ADRs), poorly managed after patients leave hospital. mHealth technologies offer a scalable way to remotely monitor, report, prevent, and manage ADRs. No review has mapped mHealth functionality for chemotherapy-related ADR management across cancer types.ObjectivesTo map existing evidence on mHealth interventions used for monitoring, reporting, preventing, or managing chemotherapy-related ADRs among cancer patients, and to identify gaps for future research.MethodsThis review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and Population-Concept-Context approach. A systematic search of PubMed and Scopus identified studies evaluating mHealth interventions (apps, SMS systems, telemonitoring platforms, or wearables) for chemotherapy-related ADRs in cancer patients of any age or setting. Data were charted on study characteristics, intervention functionality, and outcomes, then synthesized narratively.Results7 studies (one RCT, one non-randomized trial, two systematic reviews, one with meta-analysis, two observational studies, one non-randomized study) met inclusion criteria, mostly in breast cancer (71%) and delivered via smartphone apps (86%). Monitoring was universal (100%); reporting and management were each present in 71% of studies; prevention was weakest (29%, always secondary). Benefit tracked with pairing monitoring to active management: severe ADR incidence fell from 50.0% to 20.2%, quality of life improved significantly (SMD = 0.31, p < 0.0001), and alerts showed 72% positive predictive value. Monitoring-only platforms improved usability without clinical gains.ConclusionmHealth interventions show promise for chemotherapy ADR management, but benefits depend on linking monitoring to reporting and management rather than monitoring alone; prevention remains a key gap.

Authors

Institutions

Publication Details

Journal
Journal of Oncology Pharmacy Practice
Published
2026-11-20
DOI
https://doi.org/10.1177/10781552261509556
Primary Topic
Mobile Health and mHealth Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Use of mHealth interventions in the management of chemotherapy-related adverse drug reactions

Tejaswini Bangalore Darukaradhya, G Hari Prakash, Anush Nayak, O Amulya et al.
Journal of Oncology Pharmacy Practice
Mobile Health and mHealth Applications
article

Use of mHealth interventions in the management of chemotherapy-related adverse drug reactions

Tejaswini Bangalore Darukaradhya, G Hari Prakash, Anush Nayak, O Amulya, Renushree BS
article en

Abstract

BackgroundChemotherapy remains a cornerstone of cancer treatment but carries a substantial burden of adverse drug reactions (ADRs), poorly managed after patients leave hospital. mHealth technologies offer a scalable way to remotely monitor, report, prevent, and manage ADRs. No review has mapped mHealth functionality for chemotherapy-related ADR management across cancer types.ObjectivesTo map existing evidence on mHealth interventions used for monitoring, reporting, preventing, or managing chemotherapy-related ADRs among cancer patients, and to identify gaps for future research.MethodsThis review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and Population-Concept-Context approach. A systematic search of PubMed and Scopus identified studies evaluating mHealth interventions (apps, SMS systems, telemonitoring platforms, or wearables) for chemotherapy-related ADRs in cancer patients of any age or setting. Data were charted on study characteristics, intervention functionality, and outcomes, then synthesized narratively.Results7 studies (one RCT, one non-randomized trial, two systematic reviews, one with meta-analysis, two observational studies, one non-randomized study) met inclusion criteria, mostly in breast cancer (71%) and delivered via smartphone apps (86%). Monitoring was universal (100%); reporting and management were each present in 71% of studies; prevention was weakest (29%, always secondary). Benefit tracked with pairing monitoring to active management: severe ADR incidence fell from 50.0% to 20.2%, quality of life improved significantly (SMD = 0.31, p < 0.0001), and alerts showed 72% positive predictive value. Monitoring-only platforms improved usability without clinical gains.ConclusionmHealth interventions show promise for chemotherapy ADR management, but benefits depend on linking monitoring to reporting and management rather than monitoring alone; prevention remains a key gap.

Journal of Oncology Pharmacy Practice
M S Ramaiah University of Applied Sciences (IN)
Good health and well-being
Mobile Health and mHealth Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon